5533861 (SER.L) (SER) Competitors

5533861 (SER.L) logo
GBX 206.60 -10.00 (-4.62%)
As of 11/20/2026 12:40 PM Eastern

SER vs. HIK, HCM, INDV, VEC, and ERGO

Should you buy 5533861 (SER.L) stock or one of its competitors? 5533861 (SER.L)'s main competitors and comparable companies include Hikma Pharmaceuticals (HIK), HUTCHMED (HCM), Indivior (INDV), Vectura Group (VEC), and Ergomed (ERGO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does 5533861 (SER.L) compare to Hikma Pharmaceuticals?

5533861 (SER.L) (LON:SER) and Hikma Pharmaceuticals (LON:HIK) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

26.6% of 5533861 (SER.L) shares are owned by institutional investors. Comparatively, 63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. 14.3% of 5533861 (SER.L) shares are owned by insiders. Comparatively, 22.3% of Hikma Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

5533861 (SER.L) presently has a consensus target price of GBX 320, suggesting a potential upside of 54.89%. Hikma Pharmaceuticals has a consensus target price of GBX 1,986.25, suggesting a potential upside of 17.81%. Given 5533861 (SER.L)'s higher probable upside, equities research analysts clearly believe 5533861 (SER.L) is more favorable than Hikma Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
5533861 (SER.L)
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Hikma Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

5533861 (SER.L) pays an annual dividend of GBX 21.15 per share and has a dividend yield of 10.2%. Hikma Pharmaceuticals pays an annual dividend of GBX 82.48 per share and has a dividend yield of 4.9%. Hikma Pharmaceuticals pays out 46.9% of its earnings in the form of a dividend.

Hikma Pharmaceuticals has higher revenue and earnings than 5533861 (SER.L).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
5533861 (SER.L)£973.63M0.83N/AN/AN/A
Hikma Pharmaceuticals£3.42B1.02£353.21M£176.009.58

In the previous week, Hikma Pharmaceuticals had 2 more articles in the media than 5533861 (SER.L). MarketBeat recorded 2 mentions for Hikma Pharmaceuticals and 0 mentions for 5533861 (SER.L). 5533861 (SER.L)'s average media sentiment score of 0.00 equaled Hikma Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
5533861 (SER.L) Neutral
Hikma Pharmaceuticals Neutral

Hikma Pharmaceuticals has a net margin of 11.31% compared to 5533861 (SER.L)'s net margin of 0.00%. Hikma Pharmaceuticals' return on equity of 15.05% beat 5533861 (SER.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
5533861 (SER.L)N/A N/A N/A
Hikma Pharmaceuticals 11.31%15.05%9.40%

Summary

Hikma Pharmaceuticals beats 5533861 (SER.L) on 9 of the 12 factors compared between the two stocks.

How does 5533861 (SER.L) compare to HUTCHMED?

HUTCHMED (LON:HCM) and 5533861 (SER.L) (LON:SER) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

20.7% of HUTCHMED shares are held by institutional investors. Comparatively, 26.6% of 5533861 (SER.L) shares are held by institutional investors. 2.8% of HUTCHMED shares are held by company insiders. Comparatively, 14.3% of 5533861 (SER.L) shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, HUTCHMED had 2 more articles in the media than 5533861 (SER.L). MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for 5533861 (SER.L). HUTCHMED's average media sentiment score of 0.26 beat 5533861 (SER.L)'s score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company Overall Sentiment
HUTCHMED Neutral
5533861 (SER.L) Neutral

5533861 (SER.L) has a consensus price target of GBX 320, suggesting a potential upside of 54.89%. Given 5533861 (SER.L)'s stronger consensus rating and higher possible upside, analysts clearly believe 5533861 (SER.L) is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
5533861 (SER.L)
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

5533861 (SER.L) has higher revenue and earnings than HUTCHMED.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED£549.12M3.32-£52.98M£2.00105.00
5533861 (SER.L)£973.63M0.83N/AN/AN/A

HUTCHMED has a net margin of 163.84% compared to 5533861 (SER.L)'s net margin of 0.00%. HUTCHMED's return on equity of 18.42% beat 5533861 (SER.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMED163.84% 18.42% -5.90%
5533861 (SER.L) N/A N/A N/A

Summary

5533861 (SER.L) beats HUTCHMED on 7 of the 12 factors compared between the two stocks.

How does 5533861 (SER.L) compare to Indivior?

Indivior (LON:INDV) and 5533861 (SER.L) (LON:SER) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

5533861 (SER.L) has lower revenue, but higher earnings than Indivior.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Indivior£1.40B1.38-£2.36M-£1.21N/A
5533861 (SER.L)£973.63M0.83N/AN/AN/A

Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. 5533861 (SER.L) pays an annual dividend of GBX 21.15 per share and has a dividend yield of 10.2%. Indivior pays out -1,243.7% of its earnings in the form of a dividend.

5533861 (SER.L) has a consensus target price of GBX 320, suggesting a potential upside of 54.89%. Given 5533861 (SER.L)'s stronger consensus rating and higher possible upside, analysts clearly believe 5533861 (SER.L) is more favorable than Indivior.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Indivior
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
5533861 (SER.L)
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Indivior's average media sentiment score of 0.00 equaled 5533861 (SER.L)'saverage media sentiment score.

Company Overall Sentiment
Indivior Neutral
5533861 (SER.L) Neutral

86.0% of Indivior shares are held by institutional investors. Comparatively, 26.6% of 5533861 (SER.L) shares are held by institutional investors. 3.4% of Indivior shares are held by insiders. Comparatively, 14.3% of 5533861 (SER.L) shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Indivior has a net margin of 0.17% compared to 5533861 (SER.L)'s net margin of 0.00%. 5533861 (SER.L)'s return on equity of 0.00% beat Indivior's return on equity.

Company Net Margins Return on Equity Return on Assets
Indivior0.17% -1.11% 2.37%
5533861 (SER.L) N/A N/A N/A

Summary

Indivior and 5533861 (SER.L) tied by winning 6 of the 12 factors compared between the two stocks.

How does 5533861 (SER.L) compare to Vectura Group?

5533861 (SER.L) (LON:SER) and Vectura Group (LON:VEC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Company Net Margins Return on Equity Return on Assets
5533861 (SER.L)N/A N/A N/A
Vectura Group N/A N/A N/A

5533861 (SER.L) presently has a consensus target price of GBX 320, suggesting a potential upside of 54.89%. Given 5533861 (SER.L)'s stronger consensus rating and higher probable upside, equities analysts clearly believe 5533861 (SER.L) is more favorable than Vectura Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
5533861 (SER.L)
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Vectura Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
5533861 (SER.L)£973.63M0.83N/AN/AN/A
Vectura Group£190.60M0.00N/A£20.10N/A

26.6% of 5533861 (SER.L) shares are owned by institutional investors. 14.3% of 5533861 (SER.L) shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

5533861 (SER.L) pays an annual dividend of GBX 21.15 per share and has a dividend yield of 10.2%. Vectura Group pays an annual dividend of GBX 38 per share. Vectura Group pays out 189.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

In the previous week, 5533861 (SER.L)'s average media sentiment score of 0.00 equaled Vectura Group'saverage media sentiment score.

Company Overall Sentiment
5533861 (SER.L) Neutral
Vectura Group Neutral

Summary

5533861 (SER.L) beats Vectura Group on 8 of the 8 factors compared between the two stocks.

How does 5533861 (SER.L) compare to Ergomed?

5533861 (SER.L) (LON:SER) and Ergomed (LON:ERGO) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, dividends, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, 5533861 (SER.L)'s average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company Overall Sentiment
5533861 (SER.L) Neutral
Ergomed Neutral

Ergomed has a net margin of 9.87% compared to 5533861 (SER.L)'s net margin of 0.00%. Ergomed's return on equity of 18.08% beat 5533861 (SER.L)'s return on equity.

Company Net Margins Return on Equity Return on Assets
5533861 (SER.L)N/A N/A N/A
Ergomed 9.87%18.08%10.16%

26.6% of 5533861 (SER.L) shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 14.3% of 5533861 (SER.L) shares are held by company insiders. Comparatively, 18.2% of Ergomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

5533861 (SER.L) currently has a consensus price target of GBX 320, suggesting a potential upside of 54.89%. Given 5533861 (SER.L)'s stronger consensus rating and higher possible upside, equities analysts plainly believe 5533861 (SER.L) is more favorable than Ergomed.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
5533861 (SER.L)
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Ergomed
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Ergomed has lower revenue, but higher earnings than 5533861 (SER.L).

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
5533861 (SER.L)£973.63M0.83N/AN/AN/A
Ergomed£152.09M0.00£15M£0.29N/A

Summary

Ergomed beats 5533861 (SER.L) on 5 of the 9 factors compared between the two stocks.

Get 5533861 (SER.L) News Delivered to You Automatically

Sign up to receive the latest news and ratings for SER and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SER vs. The Competition

Metric5533861 (SER.L)Pharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£809.69M£13.62B£7.78B£2.67B
Dividend Yield7.04%2.58%2.47%5.11%
P/E RatioN/A27.5233.2222.78
Price / Sales0.836.788.104.91
Price / CashN/A15.6321.0120.23
Price / BookN/A5.164.262.40
Net IncomeN/A£2.86B£3.50B£5.88B
1 Month PerformanceN/A-9.80%-10.48%-4.75%
1 Year PerformanceN/A-8.93%-4.61%5.15%

5533861 (SER.L) Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SER
5533861 (SER.L)
N/AGBX 206.60
-4.6%
GBX 320
+54.9%
N/A£809.69M£973.63MN/AN/A
HIK
Hikma Pharmaceuticals
2.6652 of 5 stars
GBX 1,625
flat
GBX 1,986.25
+22.2%
+7.8%£3.36B£3.42B9.239,500
HCM
HUTCHMED
N/AGBX 227
-0.4%
N/A-3.7%£1.97B£549.12M113.501,760
INDV
Indivior
N/AGBX 1,238
+1.6%
N/A+0.0%£1.93B£1.40BN/A1,000
VEC
Vectura Group
N/AN/AN/AN/A£1.01B£190.60M8.209,200

Related Companies and Tools


This page (LON:SER) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners